X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5466) 5466
Newsletter (5) 5
Book Chapter (3) 3
Magazine Article (3) 3
Book / eBook (1) 1
Book Review (1) 1
Dissertation (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3986) 3986
male (2766) 2766
animals (2164) 2164
piperazines - pharmacokinetics (2115) 2115
piperazines - pharmacology (1937) 1937
pharmacology & pharmacy (1800) 1800
piperazines - therapeutic use (1638) 1638
female (1610) 1610
adult (1288) 1288
piperazines - administration & dosage (1147) 1147
middle aged (1074) 1074
rats (1054) 1054
piperazines - adverse effects (933) 933
imatinib mesylate (920) 920
pharmacokinetics (869) 869
benzamides (742) 742
dose-response relationship, drug (733) 733
oncology (709) 709
mice (694) 694
aged (688) 688
treatment outcome (598) 598
piperazines - blood (588) 588
sildenafil citrate (569) 569
piperazines - chemistry (560) 560
administration, oral (551) 551
neurosciences (491) 491
pyrimidines - therapeutic use (489) 489
drug interactions (469) 469
psychiatry (441) 441
antineoplastic agents - therapeutic use (437) 437
rats, sprague-dawley (416) 416
analysis (407) 407
piperazines - metabolism (404) 404
drug therapy (392) 392
imatinib (391) 391
medicine & public health (389) 389
time factors (373) 373
cancer (366) 366
pyrimidines - pharmacokinetics (366) 366
double-blind (360) 360
sildenafil (360) 360
chemistry, medicinal (356) 356
research (354) 354
efficacy (353) 353
adolescent (340) 340
double-blind method (335) 335
young adult (334) 334
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (331) 331
pharmacology/toxicology (331) 331
pyrimidines - pharmacology (329) 329
hematology (328) 328
safety (325) 325
brain - metabolism (316) 316
chronic myeloid-leukemia (296) 296
antineoplastic agents - pharmacology (295) 295
care and treatment (294) 294
structure-activity relationship (293) 293
antineoplastic agents - pharmacokinetics (292) 292
pharmacology (287) 287
cell line, tumor (277) 277
tissue distribution (272) 272
aripiprazole (267) 267
prasugrel hydrochloride (265) 265
biological availability (262) 262
pyrimidines - administration & dosage (262) 262
in-vitro (258) 258
schizophrenia (258) 258
sulfones (257) 257
piperazines - chemical synthesis (252) 252
purines (249) 249
therapy (249) 249
biochemistry & molecular biology (242) 242
half-life (238) 238
erectile dysfunction - drug therapy (237) 237
erectile dysfunction (236) 236
drugs (233) 233
rats, wistar (233) 233
antipsychotic agents - therapeutic use (232) 232
area under curve (231) 231
toxicology (230) 230
chronic myelogenous leukemia (229) 229
chemistry, analytical (222) 222
health aspects (221) 221
drug administration schedule (218) 218
clinical trials as topic (217) 217
aged, 80 and over (215) 215
dogs (215) 215
expression (215) 215
cross-over studies (213) 213
protein kinase inhibitors - therapeutic use (212) 212
kinetics (211) 211
drug therapy, combination (209) 209
resistance (209) 209
inhibition (208) 208
pyrimidines - adverse effects (208) 208
chromatography, high pressure liquid (207) 207
serotonin (207) 207
internal medicine (206) 206
metabolism (203) 203
reproducibility of results (198) 198
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5391) 5391
Japanese (38) 38
German (27) 27
Chinese (20) 20
French (16) 16
Russian (12) 12
Spanish (9) 9
Danish (5) 5
Czech (3) 3
Italian (3) 3
Norwegian (3) 3
Hungarian (2) 2
Portuguese (2) 2
Turkish (2) 2
Bulgarian (1) 1
Dutch (1) 1
Hebrew (1) 1
Polish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


07/1998, Volume 35, Issue 1, 28
... Pharmacokinetics of V asodilators Part II Roland Kirsten, 1 Karen Nelson, 2 Daniel Kirsten 3 and Bernhard Heintz 4 1 Department of Clinical Pharmacology , University... 
Reviews-on-treatment | Hypertension | Calcium-antagonists, pharmacokinetics | Clinical-pharmacokinetics | Alpha-blockers, pharmacokinetics | ACE-inhibitors, pharmacokinetics | Phosphodiesterase-inhibitors, pharmacokinetics | Bioavailability | Pregnancy | Xanthines, pharmacokinetics | Coronary-disorders | Children | Angiotensin-antagonists, pharmacokinetics | Vasodilators, pharmacokinetics | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | THEOPHYLLINE PHARMACOKINETICS | INTRAVENOUS NITROGLYCERIN | POPULATION PHARMACOKINETICS | RENAL-FAILURE | ISOSORBIDE DINITRATE | PHARMACOLOGY & PHARMACY | ESSENTIAL-HYPERTENSION | CONGESTIVE-HEART-FAILURE | ARTERIAL OCCLUSIVE DISEASE | CHRONIC CARDIAC-FAILURE | BLOOD-PRESSURE | Nitroprusside - pharmacokinetics | Enoximone - pharmacokinetics | Isosorbide Dinitrate - analogs & derivatives | Labetalol - pharmacokinetics | Vasodilator Agents - pharmacokinetics | Humans | Milrinone | Imidazoles - pharmacokinetics | Propanolamines - pharmacokinetics | Theophylline - pharmacokinetics | Nitroglycerin - pharmacokinetics | Prazosin - pharmacokinetics | Female | Adrenergic alpha-Antagonists - pharmacokinetics | Piperazines - pharmacokinetics | Isosorbide Dinitrate - pharmacokinetics | Indoramin - pharmacokinetics | Alprostadil - pharmacokinetics | Phosphodiesterase Inhibitors - pharmacokinetics | Pyridones - pharmacokinetics | Iloprost - pharmacokinetics | Pentaerythritol Tetranitrate - pharmacokinetics | Adrenergic beta-Agonists - pharmacokinetics | Amrinone - pharmacokinetics | Oxyfedrine - pharmacokinetics | Molsidomine - pharmacokinetics | Carbazoles - pharmacokinetics | Trapidil - pharmacokinetics
Book Review
Clinical Pharmacokinetics, ISSN 0312-5963, 2005, Volume 44, Issue 9, pp. 879 - 894
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2009, Volume 35, Issue 8, pp. 692 - 706
.... Post marketing study commitments have been made upon (accelerated) approval such as additional pharmacokinetic studies in patients with renal- or hepatic impairment... 
Hematology, Oncology and Palliative Medicine | Excretion | Absorption | Metabolism | Tyrosine kinase inhibitors | Distribution | Drug transporters and interactions | CHRONIC MYELOGENOUS LEUKEMIA | RENAL-CELL CARCINOMA | CHRONIC MYELOID-LEUKEMIA | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | CHRONIC MYELOCYTIC-LEUKEMIA | ADVANCED SOLID MALIGNANCIES | IMATINIB MESYLATE GLEEVEC | GASTROINTESTINAL STROMAL TUMORS | CEREBROSPINAL-FLUID PHARMACOKINETICS | CANCER RESISTANCE PROTEIN | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Pyrroles - pharmacokinetics | Humans | Cytochrome P-450 Enzyme System - metabolism | Pyridines - pharmacokinetics | Quinazolines - pharmacokinetics | Biological Availability | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Intestinal Absorption | Thiazoles - pharmacokinetics | Antineoplastic Agents - metabolism | Tissue Distribution | Benzenesulfonates - pharmacokinetics | Drug Interactions | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Piperazines - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Dasatinib | Administration, Oral | Imatinib Mesylate | Protein Kinase Inhibitors - blood | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Agents - blood | Pyrimidines - pharmacokinetics | Indoles - pharmacokinetics | Protein Kinase Inhibitors - pharmacology | Benzamides | Protein Kinase Inhibitors - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Oncology, Experimental | Cytochrome P-450 | Physiological aspects | Phenols | Research | Phosphotransferases | Protein binding | Cancer | Index Medicus
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2006, Volume 45, Issue 5, pp. 469 - 491
Journal Article
Clinical Drug Investigation, ISSN 1173-2563, 10/2013, Volume 33, Issue 10, pp. 727 - 736
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 05/2009, Volume 119, Issue 19, pp. 2553 - 2560
Background-Both clopidogrel and prasugrel require biotransformation to active metabolites by cytochrome P450 (CYP) enzymes. Among persons treated with... 
Drugs | Cardiovascular diseases | Genetics | 2007 FOCUSED UPDATE | CARDIAC & CARDIOVASCULAR SYSTEMS | drugs | STENT THROMBOSIS | OF-FUNCTION POLYMORPHISM | cardiovascular diseases | PERCUTANEOUS CORONARY INTERVENTION | genetics | PLATELET INHIBITION | ASSOCIATION TASK-FORCE | PERIPHERAL VASCULAR DISEASE | ELEVATION MYOCARDIAL-INFARCTION | THIENOPYRIDINE ANTIPLATELET AGENT | CLOPIDOGREL RESPONSIVENESS | ACTIVE METABOLITE | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Myocardial Infarction - mortality | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Biotransformation - genetics | Cytochrome P-450 Enzyme System - metabolism | Male | Young Adult | Receptors, Purinergic P2Y12 | Cardiovascular Diseases - mortality | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Microsomes, Liver - enzymology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Piperazines - pharmacokinetics | Stroke - mortality | Platelet Aggregation Inhibitors - therapeutic use | Stroke - prevention & control | Purinergic P2 Receptor Antagonists | Thiophenes - pharmacology | Genotype | Treatment Outcome | Piperazines - therapeutic use | Piperazines - pharmacology | Aryl Hydrocarbon Hydroxylases - metabolism | Polymorphism, Genetic | Thiophenes - pharmacokinetics | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Cytochrome P-450 Enzyme System - genetics | Aged | Myocardial Infarction - prevention & control | Prodrugs - therapeutic use | Prodrugs - pharmacology | Care and treatment | Demographic aspects | Patient outcomes | Cytochrome P-450 | Genetic aspects | Research | Genetic polymorphisms | Heart attack
Journal Article
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 04/2012, Volume 19, Issue 12, pp. 1846 - 1863
.... In this review, the main pharmacodynamic and pharmacokinetic properties of the six commercially available SSRIs are described... 
Paroxetine | Antidepressants | Fluoxetine | Pharmacological properties | Selective serotonin reuptake inhibitors (SSRIs) | Therapeutic drug monitoring (TDM) | Vilazodone | Fluvoxamine | Sertraline | Chemical-clinical correlations | Citalopram | ELECTRON-CAPTURE DETECTION | POSTTRAUMATIC-STRESS-DISORDER | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | fluvoxamine | TANDEM MASS-SPECTROMETRY | pharmacological properties | OBSESSIVE-COMPULSIVE DISORDER | PERFORMANCE LIQUID-CHROMATOGRAPHY | chemical-clinical correlations | therapeutic drug monitoring (TDM) | fluoxetine | paroxetine | selective serotonin reuptake inhibitors (SSRIs) | PHARMACOLOGY & PHARMACY | MAJOR DEPRESSIVE DISORDER | PLACEBO-CONTROLLED TRIAL | NEW-GENERATION ANTIDEPRESSANTS | citalopram | TRANSPORTER BINDING PROFILE | vilazodone | sertraline | SOLID-PHASE EXTRACTION | Paroxetine - pharmacokinetics | Serotonin Uptake Inhibitors - pharmacokinetics | Fluoxetine - pharmacokinetics | Humans | Citalopram - adverse effects | Depressive Disorder - drug therapy | Paroxetine - therapeutic use | Sertraline - adverse effects | Paroxetine - adverse effects | Benzofurans - pharmacokinetics | Sertraline - pharmacokinetics | Vilazodone Hydrochloride | Sertraline - therapeutic use | Fluoxetine - therapeutic use | Piperazines - pharmacokinetics | Fluoxetine - adverse effects | Fluvoxamine - therapeutic use | Benzofurans - therapeutic use | Serotonin Uptake Inhibitors - therapeutic use | Fluvoxamine - pharmacokinetics | Serotonin Uptake Inhibitors - adverse effects | Piperazines - therapeutic use | Benzofurans - adverse effects | Depressive Disorder - metabolism | Fluvoxamine - adverse effects | Piperazines - adverse effects | Indoles - adverse effects | Citalopram - pharmacokinetics | Citalopram - therapeutic use | Indoles - pharmacokinetics | Indoles - therapeutic use | Drug Monitoring
Journal Article
Therapeutic drug monitoring, ISSN 0163-4356, 2014, Volume 36, Issue 3, pp. 326 - 334
BACKGROUND: The objectives of this study were to evaluate the plasma concentrations of the tyrosine kinase inhibitors (TKIs), imatinib, erlotinib, and... 
Therapeutic drug monitoring | tyrosine kinase inhibitors | unselected patient cohort | trough plasma levels | RESISTANCE PROTEIN | TANDEM MASS-SPECTROMETRY | ANTITUMOR-ACTIVITY | SU11248 | CHRONIC MYELOID-LEUKEMIA | BREAST-CANCER | POPULATION PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | TOXICOLOGY | GROWTH-FACTOR | MEDICAL LABORATORY TECHNOLOGY | GASTROINTESTINAL STROMAL TUMORS | PHASE-I | therapeutic drug monitoring | Erlotinib Hydrochloride | Proton Pump Inhibitors - pharmacology | Body Weight | Pyrroles - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Gastric Acid - chemistry | Benzamides - pharmacokinetics | Humans | Middle Aged | Half-Life | Quinazolines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Chromatography, High Pressure Liquid | Drug Monitoring - methods | Dose-Response Relationship, Drug | Tandem Mass Spectrometry | Benzamides - therapeutic use | Female | Antineoplastic Agents - pharmacokinetics | Piperazines - pharmacokinetics | Pyrroles - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Piperazines - therapeutic use | Histamine H2 Antagonists | Imatinib Mesylate | Neoplasms - drug therapy | Outpatients | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Pyrimidines - pharmacokinetics | Indoles - pharmacokinetics | Indoles - therapeutic use | Aged
Journal Article